Treating Patients With High-Risk BCG-Unresponsive NMIBC
An expert urologist reviews the clinical hallmarks of high-risk BCG-unresponsive NMIBC and discusses the unmet needs and treatment goals.
EP: 1.Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Treating Patients With High-Risk BCG-Unresponsive NMIBC
EP: 3.SunRISe-1: TAR-200 and Cetrelimab in Patients With High-Risk NMIBC
EP: 4.Ongoing Research in BCG-Unresponsive NMIBC
EP: 5.What Are the Advantages of TAR-200 in BCG-Unresponsive NMIBC?
EP: 6.Emerging Agents in BCG-Unresponsive NMIBC
EP: 7.Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC
This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.
Patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who are bacillus Calmette-Guérin (BCG) unresponsive, especially those with persistent T1 lamina propria invasion or carcinoma in situ, are at high risk of progression to MIBC. Assuming no BCG shortage, standard options include radical cystectomy or clinical trial enrollment. For patients unwilling or medically unable to undergo cystectomy, intravesical chemotherapy with mitomycin C, gemcitabine, or gemcitabine plus docetaxel may be offered.
The key priority is preventing progression from high-risk NMIBC, which occurs in 15% to 30% within 1 to 2 years. Once muscle invasion develops, there is risk for metastases. Despite advances, median survival with metastatic disease remains poor. Avoiding progression is paramount.
Recurrence is also a major challenge with all risk levels of NMIBC. Repeat procedures for detection and treatment make this the most resource-intensive solid tumor, with impacts on quality of life and time off work. The goals are cure, preventing progression, and reducing recurrence rates.
Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
